Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies

@article{Zuddas2011SecondGA,
  title={Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies},
  author={A. Zuddas and R. Zanni and T. Usala},
  journal={European Neuropsychopharmacology},
  year={2011},
  volume={21},
  pages={600-620}
}
  • A. Zuddas, R. Zanni, T. Usala
  • Published 2011
  • Medicine, Psychology
  • European Neuropsychopharmacology
  • In children and adolescents the Second Generation Antipsychotics (SGAs) represent the class of psychotropic drugs whose use has grown more significantly in recent years: they are primarily used for treatment of patients with disruptive behavior disorders, mood disorders and pervasive developmental disorders or mental retardation. In order to compare the efficacy and tolerability of antipsychotics against placebo or each other, a systematic Medline/PubMed search for randomized, double blind… CONTINUE READING
    Antipsychotics in pediatric and adolescent patients: a review of comparative safety data.
    • 40
    • Highly Influenced
    Antipsychotics in pediatric and adolescent patients: a review of comparative safety data.
    • 20
    • Highly Influenced

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 140 REFERENCES
    Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.
    • 216
    • Highly Influential
    • PDF
    Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders
    • 443
    • Highly Influential
    • PDF
    Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.
    • 195
    • PDF
    Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
    • 137
    • Highly Influential
    A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.
    • 384
    • Highly Influential